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Introduction: Limited information is available regarding the ability of nerve surgery to affect medication use patterns in patients with chronic pain or neuropathy
due to nerve injury.
Methods: A retrospective survey was distributed to all operative patients (N = 767)
from a single nerve surgeon’s practice between 2014 and 2020. Data collected
included demographics, specifics of the injury and symptoms, medication and opioid use before surgery, and medication/opioid use following surgery.
Results: Out of the 767 patients, 209 (27.2%) completed the survey. Average age was
48.8 (SD = 19.1) years; 68.9% female and 31.1% male. More than 50% of the patients
took at least three medications. More than 50% of the patients after surgery did not
need medication or had significant reduction; 54.1% of the patients took opioid
medication daily, and 97.3% of patients reported that narcotic medications did not
resolve their problem. Patients rated the effectiveness (Likert scale 0–10) of opioid
medications in general at an average 3.25 ± 2.03. Of patients who took opioids regularly, 61.6% reported a negative effect of these medications on daily or professional
activities. After surgery, more than 50% of the patients did not need opioids or had
a significant reduction in opioid usage.
Conclusions: Untreated nerve injuries lead to ongoing chronic pain, explaining
why medications are mostly ineffective in eliminating symptoms. In this study, nerve
surgery targeting the anatomical source of symptoms effectively reduced both opioid and nonopioid medication use. (Plast Reconstr Surg Glob Open 2021;9:e3789; doi:
10.1097/GOX.0000000000003789; Published online 7 September 2021.)

INTRODUCTION

Chronic nerve injuries may be considered those injuries that manifest in patients seeking outpatient care.
These may result from an untreated acute injury to a
nerve, or may result from a progressive chronic process,
such as untreated compression neuropathy. Untreated
injuries to peripheral nerves may act as chronic pain generators, which can have a debilitating effect on physical
functioning and quality of life. Pain management with
medications is therefore frequently employed, including
with opioid medications.1 For various reasons, chronic
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pharmacologic pain management with opioids and other
medications is often used even for conditions where surgical interventions are available to correct the underlying
anatomical cause of the chronic pain.
Recently, the national opioid crisis has highlighted
the potential individual and societal harms associated
with chronic opioid use.2–5 Therefore, interventions with
the potential to reduce the chronic use of opioids have
become a topical matter. Patients with neuropathic pain
(NP) are more likely than patients with non-neuropathic
chronic pain to be taking opioids and multiple pain medications, but they report less pain relief from their medications.6 Interestingly, despite an increased focus on opioid
alternatives, consideration of nerve surgery as an option
to address NP is largely absent from medical algorithms
and consensus recommendations.7–11
Given that nerve surgery is a rational, traditional, and
literature-supported approach to correcting injuries of
peripheral nerves, whether due to trauma or compression neuropathy,12–18 this study was undertaken to evaluate
specifically whether nerve surgery was associated with a
postoperative reduction in chronic medication and opioid
use among patients with chronic pain due to nerve injuries. We hypothesized that nerve surgery, across a broad
Disclosure: The authors have no financial interest to declare
in relation to the content of this article.

www.PRSGlobalOpen.com

1

PRS Global Open • 2021
spectrum of conditions, would reduce patients’ dependence on chronic medication and opioid use.

METHODS

An IRB-approved retrospective survey from a single
nerve surgeon’s ambulatory referral-based practice was
distributed to all patients (N = 767) who underwent surgery for NP or dysfunction between 2014 and 2019. The
minimum follow-up period was 1 year. Data collected
included demographics, etiology of the injury, concurrent clinical conditions, specifics of nerve injury/disorder
type, duration and severity of the symptoms at presentation, medications and opioids used before surgery to treat
the nerve problem (eg, not medications for other chronic
medical conditions), effects of opioid use on quality of
life, medication/opioid use following surgery, severity of
symptoms following surgery, and complications of surgery.

RESULTS
Characteristics of the Patient Group

Out of the 767 patients, 209 (27.2%) completed the
survey. Average age was 48.8 (SD = 19.1) years; 68.9% were
women and 31.1% men. Notable comorbidities included
anxiety (31.1%), depression (28.2%), and thyroid disorders (11.0%) (Table 1).
Anatomical areas affected included the head and neck
in 119 patients (56.9%), lower extremity in 62 (29.7%),
upper extremity in 19 (9.1%), trunk/groin in six (2.9%),
breast in two (1%), and multiple areas in one (0.5%)
(Table 1); 16.3% had spontaneous onset, 53.1% had suffered a physical trauma, and 30.6% were precipitated by
previous surgery (Fig. 1A and B).
Presenting symptoms included pain 192 (91.9%),
numbness 82 (39.2%), tingling/burning 129 (61.7%),
muscle weakness 45 (21.5%), difficulty using arm or leg
46 (22%), headaches/migraines 111 (53.1%), and others
less than 10% (Table 1).
Affected quality of life variables included sleep pattern
in 78.5% of the patients, social life in 87.5%, extremity
function in 44.0%, personal/social life in 87.6%, professional activities in 71.8%, and mood/spirits in 83.7%.
The duration of symptoms before presentation is distributed as follows: less than 3 months (3.8%), 3–6 months
(8.1%), 6–12 months (20.1%), 1–2 years (25.8%), 3–5
years (21.1%), 5–10 years (10.0%), and more than10 years
(11.0%). Sixty-eight percent (95% CI = [61.2%, 74.2%])
of patients had symptoms for more than 1 year before
surgery.
The percentage of patients who reported the severity
of symptoms at presentation as being profound was 86.1%
(95% CI = [80.7%, 90.5%]). At the time of presentation, the
mean ± SD Likert scale (0–10) severity score was 8.1 ± 2.0
(median = 9). After the nerve surgery, the mean ± SD Likert
scale (0–10) severity score was 3.2 ± 3.0 (median = 2). The
change (reduction mean ± SD = 4.9 ± 3.6; median = 5)
was statistically significant (P < 0.001 by Wilcoxon signed
rank test).
Surgery types included neurolysis in 108 (51.67%)
patients, neuroma excision with implantation to muscle in
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Table 1. Patient Demographics

Age
Survey respondents
Sex
Male
Female
Comorbidities
No comorbidities
Anxiety
Depression
Peripheral vascular disease
Thyroid disorders
Autoimmune diseases
Diabetes
Cancer
Presenting symptoms
Pain
Numbness
Tingling/burning
Muscle weakness
Difficulty using arm or leg
Headaches/migraines
Surgery type
Neurolysis
Neuroma excision +
implantation to muscle
Excision and reconstruction
Nerve tumor
Anatomical area
Head and neck
Breast/chest
Upper extremity
Lower extremity
Trunk/groin

Avg 48.8

SD 19.1

No.
Patients
209

Percentage of
Patients
27.2

65
144

31.1
68.9

77
65
59
31
23
18
13
10

36.8
31.1
28.2
14.8
11
8.6
6.2
4.8

192
82
129
45
46
111

91.9
39.2
61.7
21.5
22
53.1

All
(N = 767)
455 (59.32%)
42 (5.48%)

Responded
(N = 209)
108 (51.67%)
7 (3.33%)

256 (33.38%)
14 (1.83%)

90 (42.86%)
4 (1.90%)

All
(N = 767)
484 (63.10%)
4 (0.52%)
71 (9.26%)
163 (21.25%)
45 (5.87%)

Responded
(N = 209)
119 (56.9%)
2 (0.96%)
20 (9.57%)
62 (29.67%)
6 (2.87%)

seven (3.33%), neuroma excision and nerve reconstruction in 90 (42.86%), and excision of nerve tumor in four
(1.90%) (Table 1).
Medication Use before and after Surgery

The total number of all medications used daily before
nerve surgery was: zero in 10.5% of patients, one to two in
31.1%, three to four in 28.2%, five to six in 16.3%, seven
to eight in 7.2%, nine to 10 in 2.4%, 11–12 in 1.4%, and
more than 12 in 2.9%. Significantly, more than 50% of the
patients took at least three medications daily (P = 0.018).
All patients reported that medications did not resolve their
problem, with an average effectiveness (Likert scale 0–10)
of mean ± SD = 2.5 ± 1.9 (median = 2) (Fig. 2).
After surgery, patients reported their use of all medications as follows: (1) for those who did not need to take
medications before the surgery, 0% had to take medication after the surgery and (2) for those who took medications before the surgery, medication use was completely
eliminated in 34.2% of patients, significantly reduced in
25.1%, moderately reduced in 13.4%, somewhat reduced
in 7.5%, not affected in 17.1%, and made worse in 2.7%.
Significantly, more than 50% of the patients after surgery
did not need medication or had significant reduction
(P = 0.0008) (Fig. 3).
Total daily opioid medication use before surgery was
zero in 45.9% of patients, one to three in 39.2%, four to

Felder and Ducic • Impact of Nerve Surgery on Opioid Use

Fig. 1. Spectrum of posttraumatic nerve injuries included. A, nerve injuries following trauma. B, nerve injuries following surgery.

six in 12.0%, seven to nine in 1.9%, and 10–13 in 0.96%.
The percentage of patients who took opioid medication
daily was 54.1% (95% CI = [47.1%, 61.0%]), and 97.3%
(95% CI = [92.3%, 99.4%]) of patients reported that opioid medications did not resolve their problem. Patients
rated the effectiveness (Likert scale 0–10) of opioid medications in general at an average (mean ± SD) of 3.25 ±
2.03 (median = 3). Of patients who took opioids regularly,
61.6% (95% CI = [51.9%, 70.6%]) reported a negative
effect of these medications on daily or professional activities (Fig. 4).
After surgery, patients reported their use of opioids
as follows: (1) for those who did not need to take opioids
before the surgery, 1% took opioids after the surgery; (2)
for those who took opioids before the surgery, opioid
use was completely eliminated in 56.3% of patients, significantly reduced in 12.5%, moderately reduced in 8.9%,
somewhat reduced in 6.3%, not affected in 14.3%, and
made worse in 1.8%. Significantly, more than 50% of the
patients after surgery no longer required opioid medications or had significant reduction in use (P = 2.9 × 10−13)
(Fig. 5).

Complication rate was 8.3% and all complications
were minor (delayed wound healing, dehiscence due to
noncompliance, infection requiring oral antibiotics), with
no complications requiring hospitalization or return to
the operating room

DISCUSSION

Opioid medications have increasingly been recognized to have detrimental effects both on the individual
patient and society.2,3,19 Although chronic opioid use is a
frequently observed clinical phenomenon in patients with
chronic pain due to nerve injuries,1,7–9,20 surprisingly few
studies have attempted to quantify the degree of medication and opioid use in such patients,21 or commented on
whether nerve surgery has an effect on reducing opioid
consumption in these patients.15 Generally speaking, the
commonly employed nonsurgical modalities for treatment
of chronic pain (including medications, but also interventional procedures such as neuromodulation or ablation)
are mechanistically unable to reverse the underlying anatomical cause of pain and instead are directed at controlling or “masking” symptoms. It is therefore conceptually

Fig. 2. Medications taken to address nerve-related problem before surgery.
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Fig. 3. Effect of nerve surgery on total nerve-related medication use in patients with chronic nerve pain. *By exact binomial test.

Fig. 4. Total daily opioid use and effectiveness before surgery in patients with chronic nerve pain.

straightforward to suppose that the unresolved underlying
mechanisms of pain generation will require ongoing use
of medications, contributing to the chronic use of opioids
that has recently been labeled as a crisis in our society.
Nerve surgery, in contradistinction, is directed at reversing the causative anatomical lesion responsible for producing chronic pain. Generally speaking, nerve surgery has
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been demonstrated to be effective in treating chronic NP
due to a wide variety of underlying traumatic or compressive etiologies.12–15,22 Over the past two decades of clinical
practice in nerve surgery, we have informally observed the
frequently present burden of chronic medication and opioid use among preoperative patients, and the phenomenon of reduction in medication/opioid use postoperatively
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Fig. 5. Effect of nerve surgery on daily opioid use in patients with chronic nerve pain. *By exact binomial test.

in some cases. We therefore conducted this study within our
own nerve surgery practice to verify and quantify to what
degree nerve surgery may have an effect on the reduction
of total medications and/or opioids in patients with chronic
pain, functional nerve deficits, or compression neuropathy
This study was designed as a retrospective survey
to achieve the longest possible follow-up after surgery.
Although outcomes such as pain scores were included
in the study results, this study was not intended to be a
validated outcomes study regarding the effectiveness of
nerve surgery for relief of symptoms. Rather, traditional
outcome measures were only included to give some idea
of the correlation between medication reduction and
patient-reported outcomes for effectiveness of surgery.
The primary findings of this study support the hypothesis that nerve surgery is effective in significantly reducing
dependence on chronic medications, including opioids
across a broad range of peripheral nerve pathologies
where surgery is indicated. Specifically, medication use
was completely eliminated in 34.2% of patients, and more
than 50% of patients after surgery either did not need
medication or had at least a meaningful reduction in the
number of medications needed, a result that reached statistical significance (Fig. 3). With regards to opioids in
particular, opioid use was completely eliminated in 56.3%
of patients, and more than 50% of patients after surgery
either no longer required opioid medications or had a
meaningful reduction in use (Fig. 5). It is interesting to
note that 68% of the patients had symptoms for more than
1 year before surgery, which suggests that even delayed
surgical intervention may have an effect on opioid reduction; a question that has been persistent in the literature.23
Although it may seem obvious, it is also relevant that
nearly 100% of patients self-reported that medications “did

not resolve their pain problem” (Figs. 2 and 4). Being a referral-based surgical practice, our group may have self-selected
for a predominance of patients in whom medications were
not effective. However, guidelines from the European
Federation of Neurological Societies regarding pharmacotherapy for NP suggest that only 30%–40% of patients with
chronic NP achieved pain relief of greater than 50% with
pharmacotherapy.10,11 In other published cross-sectional
surveys of patients with NP, three-fourths had moderate or
severe pain despite taking oral medications for their pain.24–29
Mechanistically, in the case of an anatomically identifiable lesion of a peripheral nerve, medications are not
able to reverse the underlying process leading to pain or
dysfunction. However, there is certainly evidence in the literature, including from randomized controlled trials, that
a variety of drugs including opioids are capable of improving symptoms of NP, including the level of pain itself.24
Several of the first-line medications for NP, including tricyclic antidepressants, duloxetine, gabapentin, pregabalin, and opioids have all produced statistically significant
improvements in sleep compared to placebo. Overall
mood, anxiety, and depression have also been shown to
improve in randomized controlled trial subjects treated
with those same drugs. However, there is evidence to suggest that such associations are not at all consistent among
patients with NP and may also be dependent on underlying intrinsic patient factors, making pharmacologic treatment of NP an often frustrating, trial-and-error process.24
Among patients in the United Kingdom followed for the
first year after being diagnosed with NP, only 30%–50%
had stable treatment regimens.30 Furthermore, among
Swedish patients with peripheral NP, two of three had
discontinued at least one treatment because of poor pain
relief, adverse effects, or both.31
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Our patients subjectively rated the average “effectiveness” of opioid treatment for NP as 3.25 on a Likert scale
of 0–10. Furthermore, 61.6% of our patients reported
that opioids had a negative effect on daily or professional
activities (Fig. 4). Taken together, these results suggest a
high degree of ineffectiveness as well as a morbidity to
treatment with opioid medications in patients referred for
surgery, with the potential morbidity being both personal
and socioeconomic.19,32
The reported low effectiveness and notable morbidity of opioids in our respondents may be due to selection
bias, given that all of our patients were referred for surgery
likely because other treatments were ineffective. However,
both findings also support the concept that medications
are unable to reverse etiology and thereby, when used as
a sole form of treatment, create a condition of chronic
medication use, whereas surgery is effective in altering the
underlying etiology and therefore may reduce the need
for chronic treatment. Finally, one may speculate that
promoting the paradigm of chronic pharmacologic treatment of conditions with an underlying surgically treatable
cause may cause a doubly negative effect on the patient by
effectively converting a potentially curable condition into
a chronic condition that both burdens the patient with
medication side effects while also putting the onus of finding effective surgical treatment on them.
Limitations of the study include a relatively low
response rate, which may have to do with attrition of
respondents over a long study period. There were differences in survey response rates among surgery types;
however, the percentage of respondents by surgery type
generally approximated the percentage of the patient
population who had undergone that surgery type.
The broad spectrum of conditions treated may skew
results, as some nerve injury conditions may have been nonpainful and predominantly related to loss of function. These
limitations preclude us from drawing definitive conclusions
regarding the magnitude of the effect of nerve surgery on
decreasing opioid consumption. On the other hand, these
data clearly indicate a positive effect of nerve surgery involvement, in general, in reducing medication and opioid use
in chronic nerve injury patients. Despite some study limitations, our findings do serve to call awareness to the issues of
polypharmacy and opioid use in patients with chronic pain
related to nerve injuries, and suggest that surgical treatment
is a potential means of reducing reliance on medications in
this population. More rigorous prospective studies are indicated to confirm these preliminary conclusions.

CONCLUSIONS

Chronic use of opioids is increasingly considered to
be detrimental to patients and society. In this study, we
demonstrated quantifiably that nerve surgery can reduce
chronic dependence on opioids and other medications
among patients with NP due to various types of nerve
injuries, and of varying duration. Nerve surgery should
be considered alongside pharmacologic treatments within
medical treatment algorithms as an option for chronic NP
due to nerve injury. Future prospective studies are indicated to confirm these findings.
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